Clients who're receiving cyclosporine, tacrolimus or other agents to prevent graft-vs .-host condition post bone marrow transplant are not qualified for this demo Experimental: Dose expansion_sub-population 2_higher dose of niraparib MTDs and/or candidate RP2Ds for elimusertib utilized in combination with niraparib at a greater fastened dose. Dwell cells are distinguished https://theaflavin21097.59bloggers.com/27147092/the-best-side-of-deoxynivalenol